Piper Jaffray Reiterates Overweight Rating, $35 PT on Sarepta Therapeutics on Updated Eteplirsen Data

In a report published Friday, Piper Jaffray analyst Edward A. Tenthoff reiterated an Overweight rating and $35.00 price target on Sarepta Therapeutics (NASDAQ: SRPT ). In the report, Tenthoff noted, “This morning Sarepta updated 74-week eteplirsen data in Duchenne Muscular Dystrophy (DMD) showing a statistically significant 62.4 meter benefit in